Research analysts covering Baird Medical Investment Holdings.
Recent press releases and 8-K filings for BDMD.
Baird Medical Announces Strategic Partnership with Stonewood Key Capital
BDMD
New Projects/Investments
- Baird Medical announced a strategic partnership with Stonewood Key Capital, a comprehensive investment management enterprise from New Zealand.
- This collaboration establishes the Hainan Free Trade Port as a pivotal hub for Baird Medical's cross-border operations and supply chain.
- The partnership aims to enable more efficient capital allocation to accelerate the global commercialization of Baird Medical's advanced medical solutions, reinforcing its market leadership and growth strategy.
Jan 26, 2026, 1:30 PM
Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam
BDMD
Product Launch
New Projects/Investments
- Baird Medical Investment Holdings Ltd. (BDMD) announced on January 7, 2026, that it achieved key regulatory milestones with official product registrations from the Medical Device Board of Pakistan and the Ministry of Health of Vietnam.
- These dual approvals are considered a pivotal step in the company's international expansion, accelerating its global commercialization strategy and expanding its compliant footprint within the Southeast Asian market.
- The company successfully executed its official product launch in Pakistan at the Armed Forces Institute of Radiology & Imaging (AFIRI).
Jan 7, 2026, 1:30 PM
Baird Medical Establishes U.S. Manufacturing Base
BDMD
New Projects/Investments
- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) has established a dedicated manufacturing base in the United States. This move is a pivotal step in its transition from a specialized exporter to a comprehensive global medical technology enterprise.
- The company has partnered with California-based MPS Medical to create this centralized production hub, which will supply Baird Medical's advanced proprietary technologies to global markets.
- This decision is driven by Baird Medical's rapid commercial success across over a dozen countries, including recent market penetrations in Indonesia and Malaysia. Baird Medical is an FDA 510(k)-certified medical device company with solutions used in over 30 prestigious U.S. hospitals and clinics, and is a market leader in China for thyroid microwave ablation devices.
Dec 17, 2025, 1:30 PM
Baird Medical Investment Holdings Reports Significant Decline in H1 2025 Financial Performance
BDMD
Earnings
Demand Weakening
Profit Warning
- Baird Medical Investment Holdings Limited experienced a significant decline in financial performance, with net revenues decreasing from $13.1 million for the six months ended June 30, 2024, to $8.0 million for the six months ended June 30, 2025.
- The company's profitability shifted from a net income of $4.4 million for the six months ended June 30, 2024, to a net loss of $11.4 million for the six months ended June 30, 2025.
- Adjusted EBITDA also turned negative, moving from positive $7.1 million for the six months ended June 30, 2024, to negative $3.3 million for the six months ended June 30, 2025.
- The company's cash and cash equivalents decreased from $2,970,199 as of December 31, 2024, to $2,171,492 as of June 30, 2025.
- Total liabilities increased to $41,366,411 as of June 30, 2025, from $38,202,392 as of December 31, 2024, while total equity decreased to $35,624,071 from $39,760,478 over the same period.
Dec 5, 2025, 9:03 PM
Baird Medical Appoints Mark Saxton as U.S. CEO
BDMD
Management Change
Hiring
New Projects/Investments
- Baird Medical Investment Holdings Ltd. (BDMD) has appointed Mark Saxton as Chief Executive Officer of its U.S. subsidiary.
- Mr. Saxton will lead all U.S. operations, including sales, marketing, and market development, to accelerate Baird Medical's entry into the U.S. market.
- Saxton brings over 25 years of commercial leadership experience in medical devices, with a proven track record of scaling high-growth medtech companies and contributing to significant acquisitions and IPOs.
- Baird Medical specializes in minimally invasive Microwave Ablation (MWA) technology and is an FDA 510(k)-certified medical device company with solutions used in over 30 U.S. hospitals.
Dec 3, 2025, 1:30 PM
Baird Medical Enters Egyptian Market with First Bone Ablation Procedure
BDMD
New Projects/Investments
Product Launch
- Baird Medical Investment Holdings Ltd. (BDMD) officially launched into the Egyptian market on November 3, 2025, with the successful completion of its first bone ablation procedure at Ain Shams Specialized Hospital.
- The landmark procedure involved a bone ablation using the Baird MWA system, demonstrating its versatility beyond soft tissue treatments into musculoskeletal applications.
- This market entry signifies a major milestone, reinforcing Baird Medical's commitment to expanding global access to advanced, non-surgical solutions.
- Baird Medical is an FDA 510(k)-certified medical device company, a market leader in China for thyroid microwave ablation devices, and is commercially expanding its minimally invasive treatment products in over 20 countries worldwide.
Nov 3, 2025, 1:30 PM
Baird Medical's MWA System Achieves Medicare Reimbursement
BDMD
New Projects/Investments
- Baird Medical Investment Holdings Ltd. (BDMD) announced the clinical adoption of its Microwave Ablation (MWA) system at Elk Medical, a private endocrinology practice in Brooklyn, New York, where nine MWA procedures for large thyroid nodules have been performed.
- These initial MWA procedures were successfully reimbursed by Medicare, representing an encouraging early step for broader patient access and indicating potential for clinical adoption and economic viability in a key U.S. market.
- Baird Medical is an FDA 510(k)-certified medical device company with solutions used in over 30 prestigious U.S. hospitals and clinics, and it is the market leader in China for thyroid microwave ablation devices.
Oct 27, 2025, 12:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more